{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T18:50:50Z","timestamp":1764874250158,"version":"3.40.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s13555-025-01362-w","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T20:50:48Z","timestamp":1742590248000},"page":"1025-1035","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Deucravacitinib: Laboratory Parameters Across Phase\u00a03 Plaque Psoriasis Trials"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0064-8707","authenticated-orcid":false,"given":"April W.","family":"Armstrong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0831-2151","authenticated-orcid":false,"given":"Leon","family":"Kircik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Stein Gold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8394-2057","authenticated-orcid":false,"given":"Bruce","family":"Strober","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia H. M. C.","family":"De Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Vaile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Ming","family":"Jou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolin","family":"Daamen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Scharnitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4705-5303","authenticated-orcid":false,"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"issue":"502","key":"1362_CR1","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw1736","volume":"11","author":"JR Burke","year":"2019","unstructured":"Burke JR, Cheng L, Gillooly KM, et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med. 2019;11(502):eaaw1736.","journal-title":"Sci Transl Med"},{"key":"1362_CR2","doi-asserted-by":"crossref","first-page":"13466","DOI":"10.1038\/ncomms13466","volume":"7","author":"P Kulig","year":"2016","unstructured":"Kulig P, Musiol S, Freiberger SN, et al. IL-12 protects from psoriasiform skin inflammation. Nat Commun. 2016;7:13466.","journal-title":"Nat Commun"},{"issue":"20","key":"1362_CR3","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","volume":"62","author":"ST Wrobleski","year":"2019","unstructured":"Wrobleski ST, Moslin R, Lin S, et al. Highly selective inhibition of tyrosine kinase\u00a02 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165. J Med Chem. 2019;62(20):8973\u201395.","journal-title":"J Med Chem"},{"issue":"5","key":"1362_CR4","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s13555-021-00596-8","volume":"11","author":"A Chimalakonda","year":"2021","unstructured":"Chimalakonda A, Burke J, Cheng L, et al. Selectivity profile of the tyrosine kinase\u00a02 inhibitor deucravacitinib compared with Janus kinase 1\/2\/3 inhibitors. Dermatol Ther (Heidelb). 2021;11(5):1763\u201376.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1362_CR5","unstructured":"Sotyktu [package insert]. Princeton, NJ, USA: Bristol Myers Squibb, 2022."},{"key":"1362_CR6","unstructured":"Sotyktu [package insert]. Tokyo, Japan: Bristol Myers Squibb K.K., 2022."},{"key":"1362_CR7","unstructured":"Sotyktu [product information]. Mulgrave, VIC, Australia: Bristol Myers Squibb Australia Pty. Ltd., 2022."},{"key":"1362_CR8","unstructured":"Sotyktu [European summary of product characteristics]. Dublin, Ireland: Bristol Myers Squibb EEIG, 2023."},{"key":"1362_CR9","unstructured":"Sotyktu [package insert]. Shanghai, China: Bristol Myers Squibb (China) Investment Co., Ltd., 2023."},{"issue":"1","key":"1362_CR10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","volume":"88","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase\u00a03 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88(1):29\u201339.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1362_CR11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","volume":"88","author":"B Strober","year":"2023","unstructured":"Strober B, Tha\u00e7i D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, program for evaluation of TYK2 inhibitor psoriasis second phase\u00a03 trial. J Am Acad Dermatol. 2023;88(1):40\u201351.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1362_CR12","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/jdv.19925","volume":"38","author":"B Strober","year":"2024","unstructured":"Strober B, Blauvelt A, Warren RB, et al. Deucravacitinib in moderate to severe plaque psoriasis: pooled safety and tolerability over 52\u00a0weeks from two phase\u00a03 trials (POETYK PSO-1 and PSO-2). J Eur Acad Dermatol Venereol. 2024;38(8):1543\u201354.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1362_CR13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamadermatol.2024.4688","volume":"161","author":"AW Armstrong","year":"2024","unstructured":"Armstrong AW, Lebwohl M, Warren RB, et al. Safety and efficacy of deucravacitinib in moderate to severe plaque psoriasis for up to 3\u00a0years: a nonrandomized open-label extension of phase\u00a03 clinical trials. JAMA Dermatol. 2025;161(1):56\u201366.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"1362_CR14","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","volume":"81","author":"PJ Mease","year":"2022","unstructured":"Mease PJ, Deodhar AA, van der Heijde D, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase\u00a0II trial in psoriatic arthritis. Ann Rheum Dis. 2022;81(6):815\u201322.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1362_CR15","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","volume":"75","author":"E Morand","year":"2023","unstructured":"Morand E, Pike M, Merrill JT, et al. Deucravacitinib, a tyrosine kinase\u00a02 inhibitor, in systemic lupus erythematosus: a phase\u00a0II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2023;75(2):242\u201352.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"1362_CR16","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","volume":"80","author":"CA Elmets","year":"2019","unstructured":"Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073\u2013113.","journal-title":"J Am Acad Dermatol"},{"issue":"3 Pt 1","key":"1362_CR17","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/jid.2011.365","volume":"132","author":"SM Langan","year":"2012","unstructured":"Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2012;132(3 Pt 1):556\u201362.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"1362_CR18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.5314\/wjd.v3.i4.76","volume":"3","author":"E Vilarrasa","year":"2014","unstructured":"Vilarrasa E, Puig L. Psoriasis: biologic treatment and liver disease. World J Dermatol. 2014;3(4):76\u201385.","journal-title":"World J Dermatol"},{"issue":"4","key":"1362_CR19","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","volume":"13","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13(4):234\u201343.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"1362_CR20","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/bjd\/ljae014","volume":"190","author":"M Lebwohl","year":"2024","unstructured":"Lebwohl M, Warren RB, Sofen H, et al. Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase\u00a03 POETYK trials. Br J Dermatol. 2024;190(5):668\u201379.","journal-title":"Br J Dermatol"},{"key":"1362_CR21","doi-asserted-by":"crossref","unstructured":"Korman NJ, Passeron T, Gordon KB, et al. Deucravacitinib in plaque psoriasis: 2-year laboratory results From the phase\u00a03 POETYK PSO program [abstract P1481]. Presented at: the 31st European Academy of Dermatology and Venereology Congress; 7\u201310 September 2022; Milan, Italy.","DOI":"10.25251\/skin.6.supp.46"},{"issue":"5","key":"1362_CR22","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacl.2017.06.012","volume":"11","author":"R Wolk","year":"2017","unstructured":"Wolk R, Armstrong EJ, Hansen PR, et al. Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis. J Clin Lipidol. 2017;11(5):1243\u201356.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"1362_CR23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4078\/jrd.2023.0040","volume":"31","author":"I Kwon","year":"2024","unstructured":"Kwon I, Choi N, Shin JH, Lee S, Nam B, Kim TH. Impact of anti-tumor necrosis factor treatment on lipid profiles in Korean patients with ankylosing spondylitis. J Rheum Dis. 2024;31(1):41\u20138.","journal-title":"J Rheum Dis"},{"key":"1362_CR24","volume":"2011","author":"KR Castro","year":"2011","unstructured":"Castro KR, Aikawa NE, Saad CG, et al. Infliximab induces increase in triglyceride levels in psoriatic arthritis patients. Clin Dev Immunol. 2011;2011:352686.","journal-title":"Clin Dev Immunol"},{"issue":"6","key":"1362_CR25","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/j.1365-2133.2007.08188.x","volume":"157","author":"G Stinco","year":"2007","unstructured":"Stinco G, Piccirillo F, Patrone P. Hypertriglyceridaemia during treatment with adalimumab in psoriatic arthritis. Br J Dermatol. 2007;157(6):1273\u20134.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1362_CR26","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/0190-9622(91)70247-Y","volume":"25","author":"RM Grossman","year":"1991","unstructured":"Grossman RM, Delaney RJ, Brinton EA, Carter DM, Gottlieb AB. Hypertriglyceridemia in patients with psoriasis treated with cyclosporine. J Am Acad Dermatol. 1991;25(4):648\u201351.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1362_CR27","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/art.41613","volume":"73","author":"B Weber","year":"2021","unstructured":"Weber B, He Z, Yang N, et al. Divergence of cardiovascular biomarkers of lipids and subclinical myocardial injury among rheumatoid arthritis patients with increased inflammation. Arthritis Rheumatol. 2021;73(6):970\u20139.","journal-title":"Arthritis Rheumatol"},{"key":"1362_CR28","doi-asserted-by":"crossref","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","volume":"2","author":"JE Greb","year":"2016","unstructured":"Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:16082.","journal-title":"Nat Rev Dis Primers"},{"key":"1362_CR29","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0. US Dept of Health and Human Services, 2017. Available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed Jan 2, 2024."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01362-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01362-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01362-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T14:05:17Z","timestamp":1743861917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01362-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1362"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01362-w","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"15 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"April W. Armstrong has served as a research investigator, scientific advisor, and\/or speaker for AbbVie, Almirall, Arcutis, Aslan Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, EPI Health, Incyte, Janssen, Leo Pharma, Lilly, Mindera Health, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun Pharma, and UCB. Leon Kircik has received research grants from AbbVie, Allergan, Almirall, Amgen, Arcutis, Boehringer Ingelheim, Breckinridge Pharma, Bristol Myers Squibb, Celgene, Cellceutix, Centocor, CombiMatrix, Connetics, Coria, Dermavant, Dermira, Dow Pharma, Dr. Reddy\u2019s Laboratories, Galderma, Genentech, GSK, Idera, Johnson & Johnson, Leo Pharma, Lilly, Maruho, Merck, Medicis, Novartis AG, Pfizer, PharmaDerm, Promius, Stiefel, Sun Pharma, UCB, Valeant, and XenoPort, and has received honoraria from AbbVie, Allergan, Almirall, Amgen, Arcutis, Biogen Idec, Bristol Myers Squibb, Celgene, Cipher, Connetics, Dermavant, Dermira, Dr. Reddy\u2019s Laboratories, Galderma, Genentech, GSK, Johnson & Johnson, Leo Pharma, Lilly, Merck, Novartis AG, PharmaDerm, Promius, Serono, Stiefel, Sun Pharma, Taro, UCB, and Valeant. Linda Stein Gold has served as a consultant, advisory board member, and\/or speaker for AbbVie, Amgen, Arcutis, Aslan, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, Galderma, Incyte, Janssen, Leo Pharma, Lilly, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB. Bruce Strober has served as a consultant with honoraria for AbbVie, Acelyrin, Alamar, Almirall, Alumis, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Bristol Myers Squibb, Capital One, Celltrion, CorEvitas, Dermavant, Inmagene, Janssen\/J&J Innovative Medicine, Kangpu Biopharmaceuticals, Leo Pharma, Lilly, Maruho, Meiji Seika Pharma, Monte Rosa Therapeutics, Novartis, Pfizer, Protagonist, RAPT Therapeutics, Regeneron, Sanofi, Sun Pharma, Takeda, TD Cowen, UCB, Union Therapeutics, Ventyx Biosciences, and vTv Therapeutics; as a speaker for AbbVie, Arcutis, Dermavant, Incyte, Janssen\/J&J Innovative Medicine, Lilly, Regeneron, and Sanofi; as a co-scientific director (consulting fee) and investigator for the CorEvitas Psoriasis Registry; as editor-in-chief with an honorarium for the Journal of Psoriasis and Psoriatic Arthritis; and holds stock options in Connect Biopharma and Mindera Health. Claudia H. M. C. De Oliveira, John Vaile, Ying-Ming Jou, and Carolin Daamen are employees of and shareholders in Bristol Myers Squibb. Thomas Scharnitz was an employee of and shareholder in Bristol Myers Squibb at the time of study conduct and is now an employee of Novartis. Mark Lebwohl is an employee of Mount Sinai and receives research funds from AbbVie, Arcutis, Avotres, Boehringer Ingelheim, Cara Therapeutics, Clexio, Dermavant Sciences, Incyte, Inozyme, Janssen, Lilly, Pfizer, Sanofi-Regeneron, and UCB, and is a consultant for\u00a0Almirall, AltruBio, Apogee, Arcutis, AstraZeneca, Atomwise, Avotres, Boehringer Ingelheim, Bristol Myers Squibb,\u00a0Castle Biosciences, Celltrion, CorEvitas Psoriasis Registry, Dermavant, Dermsquared, Evommune, Facilitation of International Dermatology Education, Forte Biosciences, Galderma, Genentech, Incyte, Leo Pharma, Meiji Seika Pharma, Mindera Health, Pfizer, Sanofi-Regeneron, Seanergy, Strata, Takeda, Trevi, and Verrica. Mark Lebwohl is an Editorial Board member of Dermatology and Therapy. Mark Lebwohl was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"These studies were conducted in accordance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines of the International Council for Harmonisation and in accordance with the European Union Directive 2001\/20\/EC and the US Code of Federal Regulations, Title 21, Part 50 (21CFR50), as well as applicable local requirements. The study protocols and amendments were approved by an institutional review board or independent ethics committee before initiation of the study at each site. All patients or their legal representatives provided written informed consent prior to study participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}